Marché des inhalateurs respiratoires – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00003093
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 254
Buy Now

Le marché des inhalateurs respiratoires devrait passer de 31 144,56 millions de dollars américains en 2022 à 43 446,19 millions de dollars américains d'ici 2028 ; on estime qu'il enregistre un TCAC de 5,7 % de 2022 à 2028.



Les inhalateurs respiratoires sont utilisés pour inhaler des médicaments qui sont essentiels au traitement des maladies pulmonaires chroniques. Ils sont utilisés à la fois pour prévenir et traiter les exacerbations de ces maladies chroniques. Ils offrent l'avantage d'éviter l'exposition systémique aux médicaments tout en garantissant que les médicaments atteignent directement les poumons. De nombreux produits délivrent des médicaments directement dans les voies respiratoires, tels que les inhalateurs à poudre sèche, les inhalateurs-doseurs (MDI), les nébuliseurs et les inhalateurs à brume douce. Le marché des inhalateurs respiratoires devrait croître en raison de la prévalence croissante de maladies respiratoires telles que l'asthme, la bronchopneumopathie chronique obstructive (BPCO), la fibrose kystique, le syndrome de chevauchement asthme-BPCO, etc.



Perspectives stratégiques< /h3>

Aperçu du marché des inhalateurs respiratoires



L'adoption croissante des inhalateurs génériques stimule la croissance du marché des inhalateurs respiratoires



Les médicaments inhalés impliquant une large gamme de dispositifs d'inhalation sont le pilier du traitement pharmacologique de l'asthme et de la MPOC. Les patients souffrant d'asthme et de MPOC ont souvent besoin d'un ou plusieurs inhalateurs par jour pour maintenir leurs voies respiratoires en bonne santé. Par conséquent, les professionnels de la santé craignent de changer de médicament car cela peut avoir un impact négatif sur le contrôle de la maladie en raison d'une faible observance et d'une mauvaise utilisation des types de dispositifs d'administration d'aérosols. Avec la pression croissante sur les budgets de santé et l'expiration simultanée des brevets sur les traitements par inhalation établis, plusieurs produits de remplacement génériques sont fabriqués et fournis à travers le monde. Plusieurs inhalants utilisés pour traiter l'asthme comprennent des formulations génériques, telles que l'albutérol, le levalbutérol, l'ipratropium, le budésonide et le fluticasone/salmétérol. Les inhalateurs génériques sont bioéquivalents aux versions de marque et ont le même effet sur le corps. Le nombre d'inhalateurs génériques pour l'asthme continue d'augmenter à mesure que les brevets expirent. Le 3 mars 2020, la Food and Drug Administration (FDA) a autorisé les inhalateurs génériques pour l'asthme et la poudre de corticostéroïde inhalé générique. En avril 2020, la FDA a approuvé un inhalateur générique, à base de sulfate d'albutérol, pour répondre aux besoins des patients COVID-19 ayant des difficultés respiratoires. À mesure que de plus en plus de médicaments génériques entrent sur le marché, on s'attend à une concurrence accrue, ce qui, à son tour, entraînera une réduction des coûts des médicaments. Des réductions de coûts peuvent également résulter du lancement d'un « médicament générique approuvé ». Ainsi, l'adoption croissante d'inhalateurs génériques et de médicaments contre l'asthme améliore l'adhésion aux médicaments, dynamisant ainsi le marché des inhalateurs respiratoires.



Informations basées sur le type de produit



Selon le type de produit, le marché des inhalateurs respiratoires est segmenté en nébuliseurs, inhalateurs-doseurs et inhalateurs à poudre sèche. Le segment des inhalateurs de poudre sèche est en outre divisé en inhalateurs de poudre sèche multidoses et en inhalateurs de poudre sèche unidose. Le segment des inhalateurs-doseurs (MDI) est en outre divisé en inhalateurs-doseurs sous pression et en inhalateurs-doseurs connectés. Le segment des nébuliseurs est sous-segmenté en nébuliseurs à air comprimé, nébuliseurs à air maillé et nébuliseurs à ultrasons. En 2022, le segment des inhalateurs à poudre sèche représentait la plus grande part de marché. Cependant, le segment des inhalateurs-doseurs (MDI) devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.



Marché des inhalateurs respiratoires, par type de produit&ndash ; 2022 et 2028



(image) Perspectives basées sur la technologie



Basé sur la technologie, le marché des inhalateurs respiratoires est divisé en inhalateurs à commande manuelle et inhalateurs à commande numérique. Le segment des inhalateurs à commande manuelle détenait une plus grande part de marché en 2022 et devrait enregistrer un TCAC plus élevé au cours de la période de prévision.



Informations basées sur l'indication de la maladie



Sur la base de l'indication de la maladie, le Le marché mondial des inhalateurs respiratoires est segmenté en asthme, MPOC, hypertension artérielle pulmonaire et autres. Le segment de l'asthme détenait la plus grande part du marché en 2022 et devrait croître au TCAC le plus élevé au cours de la période de prévision.



Les stratégies inorganiques et organiques telles que les fusions et acquisitions sont largement adoptées par les entreprises du marché des inhalateurs respiratoires. Quelques développements clés récents du marché sont énumérés ci-dessous :




  • En septembre 2022, Beximco Pharmaceuticals a lancé ONRIVA TRIO BEXICAP, qui est une capsule d'inhalateur sec. ONRIVA TRIO BEXICAP est la préparation d'Indacatérol (150 µg), de Glycopyrronium (50 µg), et de Mométasone (160 µg). Il agit de 3 façons pour contrôler les symptômes de l'asthme. L'indacatérol et le glycopyrronium aident les muscles des voies respiratoires pulmonaires à rester détendus pour prévenir la bronchoconstriction, tandis que la mométasone aide à réduire l'inflammation. ONRIVA TRIO BEXICAP est indiqué comme traitement d'entretien dans l'asthme persistant sévère.

  • En juin 2021, Cipla a annoncé avoir reçu l'approbation finale de sa demande abrégée de nouveau médicament (ANDA) pour la solution pour inhalation de tartrate d'arformotérol 15 mcg/2 mL de la Food and Drug Administration des États-Unis. La solution d'inhalation de tartrate d'arformotérol de Cipla 15 mcg/2 mL est une version équivalente thérapeutique générique classée AN de Brovana de Sunovion Pharmaceuticals Inc.

  • En février 2022, AstraZeneca et Honeywell ont annoncé leur intention de s'associer pour le développement des inhalateurs respiratoires de nouvelle génération utilisant le propulseur HFO-1234ze, qui a jusqu'à 99,9 % moins de potentiel de réchauffement global (GWP) que les propulseurs actuellement utilisés dans les médicaments respiratoires.

  • En janvier 2023, la FDA a approuvé Airsupra [pressurized inhalateur-doseur (pMDI)] aux États-Unis pour le traitement ou la prévention au besoin de la bronchoconstriction. Airsupra est un inhalateur-doseur pressurisé (pMDI) premier de sa catégorie, un médicament de secours combiné à dose fixe contenant de l'albutérol, un bêta2-agoniste à courte durée d'action (SABA) et du budésonide, un corticostéroïde inhalé anti-inflammatoire (ICS) aux Etats-Unis.


Profils des entreprises




  • AstraZeneca Plc

  • Beximco Pharmaceuticals Ltd.

  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.

  • GSK Plc

  • Koninklijke Philips NV

  • OMRON Corp

  • PARI Respiratory Equipment, Inc.
  • Teva Pharmaceutical Industries Ltd.

  • OPKO Health, Inc.


Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is meant by the respiratory inhalers market?

Respiratory inhalers are used to inhale drugs that are an essential part of treating chronic lung diseases. They are used both to prevent and treat exacerbations of these chronic diseases. They offer the advantage of avoiding systemic drug exposure while ensuring the drugs reach the lungs directly. Numerous products deliver drugs directly into the airways, such as dry powder inhalers, metered dose inhalers (MDIs), nebulizers and soft mist inhalers. The respiratory inhaler market is expected to flourish due to the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others.

What are the driving factors for the respiratory inhalers market across the globe?

Key factors driving the market growth are rising cases of respiratory disorders and growing adoption of generic inhalers.

Which segment led the respiratory inhalers market?

The respiratory inhalers market, by product type, is segmented into nebulizers, metered dose inhalers, and dry powder inhalers. The dry powder inhalers segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period (2022–2028).

Which technology segment held the largest revenue (US$ Mn) in the respiratory inhalers market?

Based on technology, the global respiratory inhalers market is divided into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Who are the key players in the respiratory inhalers market?

Companies operating in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH, Cipla Ltd.;GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc..

What is the regional market scenario of the respiratory inhalers market?

Global respiratory inhalers market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is likely to continue its dominance in the respiratory inhalers market during 2022–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period.

The List of Companies - Respiratory Inhalers Market

  1. AstraZeneca Plc
  2. Beximco Pharmaceuticals Ltd.
  3. Boehringer Ingelheim International GmbH
  4. Cipla Ltd.
  5. GSK Plc
  6. Koninklijke Philips NV
  7. OMRON Corp
  8. PARI Respiratory Equipment, Inc.
  9. Teva Pharmaceutical Industries Ltd.
  10. OPKO Health, Inc.  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports